cost of glp 1 drugs in canada A Deep Dive into Canada's Most Popular Weight Loss GLP-1 Receptor Agonist Market Size

doi: 10.1111/dom.15167

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action

Since the FDA approved Wegovy in 2021 and Zepbound in 2023, public awareness of GLP-1 drugs have surged

Common side effects of Trulicity include nausea, diarrhea, vomiting, stomach pain, decreased appetite, indigestion, and/or fatigue

Patients Who Stalled on Dual Agonists: Individuals who reached a plateau on a dual agonist despite optimal dosing may benefit from the added energy-expenditure and appetite-modulating effects of the third pathway

The takeaway